GET DAILY SIGNALSImmuno-Oncology Sector Performance and Ticker Analysis
The immuno-oncology sector, comprising companies that develop advanced technologies for cancer treatment, has shown promising performance recently. This sector's innovation and critical role in advancing cancer treatments have led to a significant market response, reflected in a notable +8.04% increase in performance over the past week. Below is an analysis of the key players in this group—Corvus Pharmaceuticals (CRVS), AnaptysBio (ANAB), and iTeos Therapeutics (ITOS)—focusing on market capitalization, price movements, volume changes, and technical indicators.
Market Capitalization
The market capitalization of the immuno-oncology group, on average, stands at $563.3 million. This figure highlights the relatively moderate size of the companies within this specialized sector. Among these companies, AnaptysBio (ANAB) leads with a market cap of $924.2 million, signifying its strong position and valuation in the market. On the other hand, Corvus Pharmaceuticals (CRVS) has the smallest market cap at $224.6 million, suggesting a more speculative and potentially high-risk profile.
Price Movements: Highs and Lows
The price movements within this group have been particularly dynamic. Over the past week, the average price growth across all the stocks was 1.47%. However, the monthly price growth was significantly higher, averaging 42.58%, and the quarterly price growth was 49.25%. These figures indicate a sector that is experiencing rapid price fluctuations, which could be driven by clinical trial results, regulatory approvals, or market speculation.
-
Corvus Pharmaceuticals (CRVS): CRVS has been the standout performer in terms of price appreciation, with a weekly growth of +20.07%. This robust increase positions CRVS as a top gainer in the penny stock category, rising +17.34% in just one week. However, it's worth noting that earlier this year, CRVS also experienced significant volatility, with a notable -17.11% decline in mid-March.
-
AnaptysBio (ANAB): ANAB had a remarkable +26.9% price jump in early May, which has contributed to its strong performance over the quarter. However, recent indicators suggest a potential reversal, as the RSI oscillator has moved out of the overbought zone, which could indicate a downturn.
-
iTeos Therapeutics (ITOS): ITOS has faced some challenges, with the stock seeing a -14.23% decline, making it the biggest loser in the group. Despite this, the Aroon Indicator suggests a bullish signal, indicating that ITOS may be poised for a rebound.
Volume Trends
Volume trends across the immuno-oncology group have been notably high, reflecting strong investor interest and market activity.
-
iTeos Therapeutics (ITOS): ITOS saw an extraordinary increase in trading volume, with a one-day spike of 298% above the 65-Day Volume Moving Average. This surge could be an indication of increased investor interest or significant market events that prompted more active trading.
-
Corvus Pharmaceuticals (CRVS): CRVS experienced a sustained increase in trading volume, with five consecutive days of rising volume, averaging a daily strong performance. This sustained increase suggests ongoing investor attention and possibly institutional buying.
-
AnaptysBio (ANAB): ANAB also saw a significant volume increase, with a record-breaking one-day growth of 320% above the 65-Day Volume Moving Average. This sharp rise could indicate heightened interest or market-moving news that attracted traders to the stock.
Technical Indicators
Technical indicators provide further insights into the potential future movements of these stocks.
-
CRVS (Corvus Pharmaceuticals): The MACD Histogram for CRVS turned positive on July 10, 2024. Historically, this indicator has been a reliable predictor for CRVS, with an 89% chance of continued upward movement in similar past instances. This suggests that CRVS could see further gains in the near term, particularly given its recent price performance.
-
ANAB (AnaptysBio): The RSI Oscillator for ANAB has exited the overbought zone, signaling a potential trend reversal. With the stock currently trading between its resistance and support lines, traders might consider this a cue to take profits or hedge against potential declines.
-
ITOS (iTeos Therapeutics): The Aroon Indicator for ITOS suggests a bullish move is likely, with the AroonUp indicator above 70 and the AroonDown indicator below 30. This pattern, seen in 76% of similar past cases, indicates that ITOS could be gearing up for a recovery after its recent decline.
Summary
The immuno-oncology sector, as represented by CRVS, ANAB, and ITOS, presents a dynamic landscape with significant potential for both gains and losses. The recent performance of these stocks, coupled with strong volume trends and key technical indicators, suggests that the sector is poised for further movement.
Contributor
CRVS saw its Stochastic Oscillator peaks and leaves the overbought zone
The Stochastic Oscillator for CRVS moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 56 similar instances where the indicator exited the overbought zone. In 50 of the 56 cases the stock moved lower. This puts the odds of a downward move at 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for CRVS entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CRVS's RSI Indicator exited the oversold zone, 32 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on CRVS as a result. In 75 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for CRVS just turned positive on October 20, 2026. Looking at past instances where CRVS's MACD turned positive, the stock continued to rise in 37 of 41 cases over the following month. The odds of a continued upward trend are 90%.
Following a +7.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRVS advanced for three days, in 202 of 249 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
CRVS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.621) is normal, around the industry mean (3.104). P/E Ratio (-15.156) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. CRVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 79 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRVS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of anticancer immuno-oncology drugs
Industry Biotechnology
Advertisement